Nan Sun
Hebei University of Economics and Business(CN)Shanxi Agricultural University(CN)Shenzhen Institute of Information Technology(CN)Jinan University(CN)Xuzhou Medical College(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)ShanghaiTech University(CN)Chinese Mathematical Society(CN)University of Jinan(CN)National Cancer Center(US)Henan Academy of Sciences(CN)Hellenic Airforce General Hospital(GR)Air Force Engineering University(CN)Xuzhou Central Hospital(CN)Spinal Research(GB)Danone (China)(CN)Ministry of Education(ET)Liaoning Cancer Hospital & Institute(CN)First Affiliated Hospital of Jinan University(CN)Beijing Institute of Mathematical Sciences and ApplicationsCapital University of Economics and Business(CN)Tsinghua University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Ferroptosis and cancer prognosis, Cancer-related molecular mechanisms research, RNA modifications and cancer
Most-Cited Works
- → Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC(2020)401 cited
- → The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity(2019)281 cited
- → Prognostic alternative mRNA splicing signature in non-small cell lung cancer(2017)215 cited
- → Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins(2018)165 cited
- → KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer(2022)161 cited
- → Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance(2018)130 cited